This minireview discusses how information on the mechanisms by which ADRB2 activation inhibits apoptosis can be used to guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer. This evidence concerns the gene ADRB2 and prostate carcinoma.